Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating FactorBenjamin Lerman, Rochelle Bagatell, Rajen Mody et al.|Journal of Clinical Oncology|2022Cited by 42